Ascentage Pharma Group International (HKG:6855)

Market Cap	11.75B -29.8%
Revenue (ttm)	638.89M -41.5%
Net Income	-1.38B
EPS	-3.88
Shares Out	368.06M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,442,136
Open	32.12
Previous Close	31.92
Day's Range	31.80 - 33.84
52-Week Range	31.92 - 95.35
Beta	0.65
Analysts	Strong Buy
Price Target	96.01 (+193.61%)
Earnings Date	Aug 21, 2026

About HKG:6855

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 767
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6855

Financial Performance

In 2025, HKG:6855's revenue was 574.12 million, a decrease of -41.46% compared to the previous year's 980.65 million. Losses were -1.24 billion, 206.5% more than in 2024.

Financial numbers in CNY

Analyst Summary

According to 7 analysts, the average rating for 6855 stock is "Strong Buy." The 12-month stock price target is $96.01, which is an increase of 193.61% from the latest price.

Price Target

$96.01

(193.61% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 18, 2026

Data Sources Report a data error